Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_curated type ECO_0000205 NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- source_evidence_curated label "DisGeNET evidence - CURATED" NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- source_evidence_curated comment "Gene-disease associations manually curated." NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion evidence source_evidence_curated NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion SIO_000772 22920921 NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion wasDerivedFrom ctd_human-20130708 NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion wasGeneratedBy ECO_0000218 NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- ctd_human-20130708 importedOn "2013-07-24" NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.